Singapore markets open in 5 hours 26 minutes

Stoke Therapeutics, Inc. (0GT.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
10.80-0.20 (-1.82%)
As of 04:44PM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 555.04M
Enterprise value 391.44M
Trailing P/E 19.63
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)67.91
Price/book (mrq)4.40
Enterprise value/revenue 9.36
Enterprise value/EBITDA -1.13

Trading information

Stock price history

Beta (5Y monthly) 0.81
52-week change 36.80%
S&P500 52-week change 326.27%
52-week high 313.00
52-week low 33.16
50-day moving average 39.49
200-day moving average 35.64

Share statistics

Avg vol (3-month) 321
Avg vol (10-day) 3N/A
Shares outstanding 552.12M
Implied shares outstanding 654.95M
Float 839.98M
% held by insiders 14.65%
% held by institutions 184.66%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-672.96%

Management effectiveness

Return on assets (ttm)-30.41%
Return on equity (ttm)-61.29%

Income statement

Revenue (ttm)7.84M
Revenue per share (ttm)0.17
Quarterly revenue growth (yoy)-18.20%
Gross profit (ttm)N/A
EBITDA -116.02M
Net income avi to common (ttm)-108.53M
Diluted EPS (ttm)-2.25
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)178.58M
Total cash per share (mrq)3.43
Total debt (mrq)6.34M
Total debt/equity (mrq)4.52%
Current ratio (mrq)5.43
Book value per share (mrq)3.02

Cash flow statement

Operating cash flow (ttm)-84.28M
Levered free cash flow (ttm)-41.85M